Cancer Research  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 5733-5742, July 15, 2008. doi: 10.1158/0008-5472.CAN-08-0190
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Lau, Y.-K. I.
Right arrow Articles by Yu, Q.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lau, Y.-K. I.
Right arrow Articles by Yu, Q.

Cell, Tumor, and Stem Cell Biology

Merlin Is a Potent Inhibitor of Glioma Growth

Ying-Ka Ingar Lau1, Lucas B. Murray1, Sean S. Houshmandi2, Yin Xu1, David H. Gutmann2 and Qin Yu1

1 Department of Oncological Sciences, Mount Sinai School of Medicine, New York, New York and 2 Department of Neurology, Washington University School of Medicine, St. Louis, Missouri

Requests for reprints: Qin Yu, 16-20A-Icahn, 1425 Madison Ave, Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY 10029. Phone: 212-659-8218; Fax: 212-987-2240; E-mail: qin.yu{at}mssm.edu.

Key Words: schwannomin • merlin • glioblastoma • Lats2 • Wnt

Neurofibromatosis 2 (NF2) is an inherited cancer syndrome in which affected individuals develop nervous system tumors, including schwannomas, meningiomas, and ependymomas. The NF2 protein merlin (or schwannomin) is a member of the Band 4.1 superfamily of proteins, which serve as linkers between transmembrane proteins and the actin cytoskeleton. In addition to mutational inactivation of the NF2 gene in NF2-associated tumors, mutations and loss of merlin expression have also been reported in other types of cancers. In the present study, we show that merlin expression is dramatically reduced in human malignant gliomas and that reexpression of functional merlin dramatically inhibits both subcutaneous and intracranial growth of human glioma cells in mice. We further show that merlin reexpression inhibits glioma cell proliferation and promotes apoptosis in vivo. Using microarray analysis, we identify altered expression of specific molecules that play key roles in cell proliferation, survival, and motility. These merlin-induced changes of gene expression were confirmed by real-time quantitative PCR, Western blotting, and functional assays. These results indicate that reexpression of merlin correlates with activation of mammalian sterile 20-like 1/2–large tumor suppressor 2 signaling pathway and inhibition of canonical and noncanonical Wnt signals. Collectively, our results show that merlin is a potent inhibitor of high-grade human glioma. [Cancer Res 2008;68(14):5733–42]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.